Skip to main content
SpringerLink
Log in

New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Several antibiotic combinations have demonstrated increased activity against multidrug-resistant Pseudomonas aeruginosa (MDRP) in vitro compared with a single antibiotic. The aim of this study was to investigate the activity against MDRP of some aminoglycosides in combination with monobactam, piperacillin (PIPC), and carbapenem. Clinical isolates of MDRP were collected between November 2010 and October 2012 from patients in Tokyo Medical University Hospital, Tokyo (1,015 beds). Our new method was designed to evaluate three concentrations around the breakpoint of each drug using the Checkerboard method. The aminoglycosides tested were amikacin (AMK), tobramycin (TOB), and arbekacin (ABK). Ciprofloxacin, PIPC, and biapenem (BIPM), which have been reported to demonstrate combination effects, were also tested. Sixty-six MDRP strains were identified from the 2,417 P. aeruginosa strains. Of the 66, 27 tested positive for metallo-β-lactamase (MBL). Aztreonam (AZT) with AMK or ABK was the most effective against MDRP. PIPC with AMK or ABK were somewhat effective. AZT with AMK or ABK were more effective against MBL-positive strains than MBL-negative strains. However, PIPC with AMK or ABK were more effective against MBL-negative strains than MBL-positive strains. Combination activities showed differences between MBL-positive and MBL-negative strains.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tateda K, Ishii Y, Matsumoto T, Yamaguchi K (2006) Break-point checkerboard plate’ for screening of appropriate antibiotic combinations against multidrug-resistant Pseudomonas aeruginosa. Scand J Infect Dis 38(4):268–272. doi:10.1080/00365540500440353

    Article  CAS  PubMed  Google Scholar 

  2. Araoka H, Baba M, Takagi S, Matsuno N, Ishiwata K, Nakano N, Tsuji M, Yamamoto H, Seo S, Asano-Mori Y, Uchida N, Masuoka K, Wake A, Taniguchi S, Yoneyama A (2010) Monobactam and aminoglycoside combination therapy against metallo-beta-lactamase-producing multidrug-resistant Pseudomonas aeruginosa screened using a ‘break-point checkerboard plate’. Scand J Infect Dis 42(3):231–233. doi:10.3109/00365540903443157

    Article  CAS  PubMed  Google Scholar 

  3. Nakamura I, Yamaguchi T, Tsukimori A, Sato A, Fukushima S, Mizuno Y, Matsumoto T (2014) Effectiveness of antibiotic combination therapy as evaluated by the break-point checkerboard plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use. J Infect Chemother 20(4):266–269. doi:10.1016/j.jiac.2013.12.005

    Article  CAS  PubMed  Google Scholar 

  4. Falagas ME, Kasiakou SK (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333–1341. doi:10.1086/429323

    Article  CAS  PubMed  Google Scholar 

  5. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37(11):e154–e160. doi:10.1086/379611

    Article  CAS  PubMed  Google Scholar 

  6. Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, Sala M, Knobel H (2009) Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37(5):461–465. doi:10.1007/s15010-009-8342-x

    Article  CAS  PubMed  Google Scholar 

  7. Araoka H, Baba M, Tateda K, Ishii Y, Oguri T, Okuzumi K, Oishi T, Mori S, Mitsuda T, Moriya K, Nakamori Y, Ohmagari N, Yamaguchi K, Yoneyama A (2012) In vitro combination effects of aztreonam and aminoglycoside against multidrug-resistant Pseudomonas aeruginosa in Japan. Jpn J Infect Dis 65(1):84–87

    CAS  PubMed  Google Scholar 

  8. Oie S, Uematsu T, Sawa A, Mizuno H, Tomita M, Ishida S, Okano Y, Kamiya A (2003) In vitro effects of combinations of antipseudomonal agents against seven strains of multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52(6):911–914. doi:10.1093/jac/dkg478

    Article  CAS  PubMed  Google Scholar 

  9. Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw E, Amicosante G, Frere JM, Galleni M (1999) Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-beta-lactamase IMP-1 produced by Escherichia coli. Antimicrob Agents Chemother 43(4):902–906

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Watanabe T, Ohashi K, Matsui K, Kubota T (1997) Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 39(4):471–476

    Article  CAS  PubMed  Google Scholar 

  11. Docquier JD, Riccio ML, Mugnaioli C, Luzzaro F, Endimiani A, Toniolo A, Amicosante G, Rossolini GM (2003) IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother 47(5):1522–1528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hall MJ, Middleton RF, Westmacott D (1983) The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother 11(5):427–433

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the Department of International Medical Communications, Tokyo Medical University, for editing our manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Infection Control and Prevention, Tokyo Medical University Hospital, Tokyo, Japan

    I. Nakamura, T. Yamaguchi, A. Tsukimori, A. Sato & S. Fukushima

  2. Department of Microbiology and Infectious Diseases, Toho University Faculty of Medicine, 5-21-16 Omorinishi, Ota-ku, Tokyo, 143-8540, Japan

    T. Yamaguchi

  3. Department of Microbiology, Tokyo Medical University, Tokyo, Japan

    A. Tsukimori, A. Sato & T. Matsumoto

Authors
  1. I. Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Tsukimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Fukushima
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Yamaguchi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, I., Yamaguchi, T., Tsukimori, A. et al. New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa . Eur J Clin Microbiol Infect Dis 34, 83–87 (2015). https://doi.org/10.1007/s10096-014-2192-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-014-2192-x

Keywords

Search

Navigation